24 August 2022 | Other

Moderna files FDA application for booster against Omicron variants

Moderna Inc. submitted the FDA request for a booster dose aimed at modern COVID-19 variants. The step is designed to ensure greater protection in fighting the virus.

The company claims the doses of Moderna’s booster, which are currently unrivaled on the market, ready to be dispatched in September. Only regulatory approval is needed. The vaccine is intended for adults over 18 years, designed to protect from the two dominant Omicron variants, BA.4 and BA.5.

Next week, the Centers for Disease Control and Prevention will stage a meeting. The main issue is expected to be Moderna’s booster shots. 

As of August 11, the company announced a clinical trial phase. Notably, UK regulators had already approved Moderna's bivalent booster against the early Omicron variant.

Company MarketCheese
Period: 03.10.2026 Expectation: 175 pips
Invest in ETHUSD up to $2,565
Today at 08:13 AM
Period: 30.09.2026 Expectation: 13000 pips
Go long on Brent crude with $99.50 target
Yesterday at 12:02 PM 22
Expectation: 1200 pips
SPX sell-off targets 7,500
Yesterday at 12:02 PM 18
Period: 02.10.2026 Expectation: 3300 pips
Buy NVIDIA stocks on earnings release
Yesterday at 08:20 AM 20
Gold buy
Period: 30.09.2026 Expectation: 13000 pips
Go long on gold with $4,560 target
Yesterday at 06:44 AM 22
Period: 02.10.2026 Expectation: 3300 pips
Invest in USDCAD ahead of BoC meeting
Yesterday at 06:38 AM 22
Go to forecasts